Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease : An evidence-based review
Volkmann, Jens (University Clinic of Würzburg (Alemanya))
Albanese, Alberto (Università Cattolica Del Sacro Cuore (Milà, Itàlia))
Antonini, Angelo (IRCCS San Camillo (Venècia, Itàlia))
Chaudhuri, K.Ray (King's College Hospital (Londres, Regne Unit))
Clarke, Carl E. (University of Birmingham (Regne Unit))
De Bie, Rob M.A. (Academic Medical Center (Amsterdam, Països Baixos))
Deuschl, Günther (Christian-Albrechts-University)
Eggert, Karla (Philipps-University Marburg)
Houeto, Jean Luc (CHU de Poitiers)
Kulisevsky, Jaime (Institut d'Investigació Biomèdica Sant Pau)
Nyholm, Dag (Uppsala University (Suècia))
Odin, Per (Klinikum-Bremerhaven (Alemanya))
Østergaard, Karen (Aarhus University Hospital (Aarhus, Dinamarca))
Poewe, Werner (Innsbruck Medical University (Àustria))
Pollak, Pierre (Hòpitaux Universitaires de Genève)
Rabey, Jose Martin (Tel Aviv University)
Rascol, Olivier (University of Toulouse III (França))
Ruzicka, Evzen (Charles University (Txèquia))
Samuel, Michael (King's College Hospital NHS Foundation Trust)
Speelman, Hans (University of Amsterdam)
Sydow, Olof (Karolinska University Hospital)
Valldeoriola, Francesc (Hospital Clínic i Provincial de Barcelona)
Van Der Linden, Chris (Sint Lucas Andreas Ziekenhuis (Amsterdam, Països Baixos))
Oertel, Wolfgang (Philipps-University Marburg)
Universitat Autònoma de Barcelona

Data:	2013
Resum:	Motor complications in Parkinson's disease (PD) result from the short half-life and irregular plasma fluctuations of oral levodopa. When strategies of providing more continuous dopaminergic stimulation by adjusting oral medication fail, patients may be candidates for one of three device-aided therapies: deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion, or continuous duodenal/jejunal levodopa/carbidopa pump infusion (DLI). These therapies differ in their invasiveness, side-effect profile, and the need for nursing care. So far, very few comparative studies have evaluated the efficacy of the three device-aided therapies for specific motor problems in advanced PD. As a result, neurologists currently lack guidance as to which therapy could be most appropriate for a particular PD patient. A group of experts knowledgeable in all three therapies reviewed the currently available literature for each treatment and identified variables of clinical relevance for choosing one of the three options such as type of motor problems, age, and cognitive and psychiatric status. For each scenario, pragmatic and (if available) evidence-based recommendations are provided as to which patients could be candidates for either DBS, DLI, or subcutaneous apomorphine. © 2012 The Author(s).
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Matèria:	Apomorphine ; Deep brain stimulation ; Duodenal levodopa infusion ; Parkinson's disease
Publicat a:	Journal of neurology, Vol. 260 Núm. 11 (november 2013) , p. 2701-2714, ISSN 1432-1459

DOI: 10.1007/s00415-012-6798-6
PMID: 23287972

14 p, 243.5 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats